Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three’s A Crowd: Cimzia Joins Humira, Remicade For Crohn’s Disease

Executive Summary

UCB is pushing pricing and other incentives for Cimzia (certolizumab) - rather than clinical benefit - to break into a crowded Crohn's disease market that already includes two well-established tumor necrosis factor inhibitors

You may also be interested in...



Market Snapshot: Anti-TNFs Grow Despite Tough Market

At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry

Market Snapshot: Anti-TNFs Grow Despite Tough Market

At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry

TNF Blockers Not Seen To Boost Cancer Risk In RA Patients Tracked In Large Spanish Registry

The only elevated cancer type in patients taking the biologic drugs was non-melanoma skin cancer, investigator reports at rheumatology scientific conference.

Related Content

UsernamePublicRestriction

Register

PS049601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel